Does the media refer more to NRSN or CDIO?

In the previous week, Cardio Diagnostics had 3 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Cardio Diagnostics and 3 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.64 beat Cardio Diagnostics' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroSense Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cardio Diagnostics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate SCYX or CDIO?

SCYNEXIS presently has a consensus price target of $24.00, suggesting a potential upside of 529.92%. Given SCYNEXIS's stronger consensus rating and higher probable upside, equities analysts clearly believe SCYNEXIS is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SCYNEXIS 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media refer more to SCYX or CDIO?

In the previous week, Cardio Diagnostics had 5 more articles in the media than SCYNEXIS. MarketBeat recorded 6 mentions for Cardio Diagnostics and 1 mentions for SCYNEXIS. Cardio Diagnostics' average media sentiment score of 0.00 beat SCYNEXIS's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardio Diagnostics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate CDIO or AYTU?

Aytu BioPharma has a consensus price target of $9.83, suggesting a potential upside of 353.15%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Does the media prefer CDIO or AYTU?

In the previous week, Cardio Diagnostics had 5 more articles in the media than Aytu BioPharma. MarketBeat recorded 6 mentions for Cardio Diagnostics and 1 mentions for Aytu BioPharma. Cardio Diagnostics' average media sentiment score of 0.00 beat Aytu BioPharma's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cardio Diagnostics 0 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Aytu BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CDIO or ALLR?

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 707.09%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allarity Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer KZIA or CDIO?

Novogen currently has a consensus price target of $23.75, suggesting a potential upside of 70.62%. Given Novogen's stronger consensus rating and higher possible upside, equities analysts plainly believe Novogen is more favorable than Cardio Diagnostics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, KZIA or CDIO?

Cardio Diagnostics has lower revenue, but higher earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 765.60 -$13.41M N/A N/A Cardio Diagnostics $10K 597.92 -$6.50M -$3.38 N/A

Cardio Diagnostics (CDIO) Competitors

$2.02 -0.01 (-0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$2.04 +0.02 (+0.99%)

As of 04:10 PM Eastern

Compare

CDIO vs. NRSN, SCYX, AYTU, ALLR, and KZIA

Should you buy Cardio Diagnostics stock or one of its competitors? MarketBeat compares Cardio Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cardio Diagnostics include NeuroSense Therapeutics (NRSN), SCYNEXIS (SCYX), Aytu BioPharma (AYTU), Allarity Therapeutics (ALLR), and Novogen (KZIA). These companies are all part of the "pharmaceutical products" industry.

How does Cardio Diagnostics compare to NeuroSense Therapeutics?

NeuroSense Therapeutics (NASDAQ:NRSN) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

NeuroSense Therapeutics has a beta of 1.56, suggesting that its stock price is 56% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market.

Cardio Diagnostics has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A
Cardio Diagnostics	$10K	597.92	-$6.50M	-$3.38	N/A

In the previous week, Cardio Diagnostics had 3 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 6 mentions for Cardio Diagnostics and 3 mentions for NeuroSense Therapeutics. NeuroSense Therapeutics' average media sentiment score of 0.64 beat Cardio Diagnostics' score of 0.00 indicating that NeuroSense Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroSense Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cardio Diagnostics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

NeuroSense Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. NeuroSense Therapeutics' return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroSense Therapeutics	N/A	N/A	N/A
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

NeuroSense Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 1,019.89%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe NeuroSense Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NeuroSense Therapeutics beats Cardio Diagnostics on 10 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, dividends, earnings, profitability, risk and institutional ownership.

In the previous week, Cardio Diagnostics had 5 more articles in the media than SCYNEXIS. MarketBeat recorded 6 mentions for Cardio Diagnostics and 1 mentions for SCYNEXIS. Cardio Diagnostics' average media sentiment score of 0.00 beat SCYNEXIS's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardio Diagnostics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cardio Diagnostics has lower revenue, but higher earnings than SCYNEXIS. SCYNEXIS is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.34M	1.86	-$8.61M	-$3.84	N/A
Cardio Diagnostics	$10K	597.92	-$6.50M	-$3.38	N/A

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

SCYNEXIS has a net margin of -41.79% compared to Cardio Diagnostics' net margin of -36,950.00%. SCYNEXIS's return on equity of -57.16% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

SCYNEXIS has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market.

SCYNEXIS presently has a consensus price target of $24.00, suggesting a potential upside of 529.92%. Given SCYNEXIS's stronger consensus rating and higher probable upside, equities analysts clearly believe SCYNEXIS is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

SCYNEXIS and Cardio Diagnostics tied by winning 8 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to Aytu BioPharma?

Cardio Diagnostics (NASDAQ:CDIO) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

Aytu BioPharma has a net margin of -60.17% compared to Cardio Diagnostics' net margin of -36,950.00%. Aytu BioPharma's return on equity of -69.93% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Cardio Diagnostics has higher earnings, but lower revenue than Aytu BioPharma. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	597.92	-$6.50M	-$3.38	N/A
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A

8.1% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 13.3% of Cardio Diagnostics shares are owned by company insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cardio Diagnostics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

In the previous week, Cardio Diagnostics had 5 more articles in the media than Aytu BioPharma. MarketBeat recorded 6 mentions for Cardio Diagnostics and 1 mentions for Aytu BioPharma. Cardio Diagnostics' average media sentiment score of 0.00 beat Aytu BioPharma's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cardio Diagnostics	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aytu BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aytu BioPharma has a consensus price target of $9.83, suggesting a potential upside of 353.15%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Aytu BioPharma beats Cardio Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to Allarity Therapeutics?

Cardio Diagnostics (NASDAQ:CDIO) and Allarity Therapeutics (NASDAQ:ALLR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Allarity Therapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Cardio Diagnostics' return on equity of -78.82% beat Allarity Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%
Allarity Therapeutics	N/A	-109.94%	-47.27%

Cardio Diagnostics has higher earnings, but lower revenue than Allarity Therapeutics. Allarity Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$10K	597.92	-$6.50M	-$3.38	N/A
Allarity Therapeutics	$320K	63.14	-$11.23M	-$0.72	N/A

8.1% of Cardio Diagnostics shares are held by institutional investors. Comparatively, 11.5% of Allarity Therapeutics shares are held by institutional investors. 13.3% of Cardio Diagnostics shares are held by insiders. Comparatively, 0.2% of Allarity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Cardio Diagnostics has a beta of 2.24, suggesting that its share price is 124% more volatile than the broader market. Comparatively, Allarity Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

In the previous week, Cardio Diagnostics had 6 more articles in the media than Allarity Therapeutics. MarketBeat recorded 6 mentions for Cardio Diagnostics and 0 mentions for Allarity Therapeutics. Allarity Therapeutics' average media sentiment score of 0.50 beat Cardio Diagnostics' score of 0.00 indicating that Allarity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Cardio Diagnostics	Neutral
Allarity Therapeutics	Positive

Allarity Therapeutics has a consensus price target of $10.25, indicating a potential upside of 707.09%. Given Allarity Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Allarity Therapeutics is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allarity Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Allarity Therapeutics beats Cardio Diagnostics on 9 of the 16 factors compared between the two stocks.

How does Cardio Diagnostics compare to Novogen?

Novogen (NASDAQ:KZIA) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

In the previous week, Cardio Diagnostics had 6 more articles in the media than Novogen. MarketBeat recorded 6 mentions for Cardio Diagnostics and 0 mentions for Novogen. Cardio Diagnostics' average media sentiment score of 0.00 beat Novogen's score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Novogen	Neutral
Cardio Diagnostics	Neutral

Novogen currently has a consensus price target of $23.75, suggesting a potential upside of 70.62%. Given Novogen's stronger consensus rating and higher possible upside, equities analysts plainly believe Novogen is more favorable than Cardio Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

30.9% of Novogen shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 13.3% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Novogen has a beta of 2.17, suggesting that its stock price is 117% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market.

Novogen has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -36,950.00%. Novogen's return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Cardio Diagnostics	-36,950.00%	-78.82%	-72.87%

Cardio Diagnostics has lower revenue, but higher earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	765.60	-$13.41M	N/A	N/A
Cardio Diagnostics	$10K	597.92	-$6.50M	-$3.38	N/A

Summary

Novogen beats Cardio Diagnostics on 9 of the 14 factors compared between the two stocks.

Get Cardio Diagnostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDIO vs. The Competition

Export

Metric	Cardio Diagnostics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.98M	$3.55B	$6.67B	$12.18B
Dividend Yield	N/A	2.28%	2.68%	5.89%
P/E Ratio	-0.60	21.25	25.78	24.01
Price / Sales	597.92	329.16	588.14	124.91
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	0.53	8.01	10.50	6.34
Net Income	-$6.50M	$23.91M	$3.57B	$337.22M
7 Day Performance	2.02%	1.38%	0.83%	-1.17%
1 Month Performance	25.47%	1.76%	0.70%	0.43%
1 Year Performance	-38.41%	56.81%	30.96%	29.10%

Cardio Diagnostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDIO Cardio Diagnostics	0.6274 of 5 stars	$2.02 -0.5%	N/A	-42.0%	$5.98M	$10K	N/A	1	News Coverage
NRSN NeuroSense Therapeutics	4.3398 of 5 stars	$0.71 +2.0%	$8.50 +1,092.1%	-67.1%	$23.22M	N/A	N/A	10	News Coverage Upcoming Earnings Gap Up
SCYX SCYNEXIS	1.7616 of 5 stars	$4.11 +0.5%	$24.00 +483.9%	-34.7%	$22.93M	$20.60M	N/A	60	News Coverage
AYTU Aytu BioPharma	2.7232 of 5 stars	$2.13 +2.4%	$9.83 +361.7%	+7.4%	$22.86M	$56.60M	N/A	160
ALLR Allarity Therapeutics	2.4179 of 5 stars	$1.44 +1.0%	$10.25 +609.8%	+23.8%	$22.82M	$320K	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDIO) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cardio Diagnostics (CDIO) Competitors

CDIO vs. NRSN, SCYX, AYTU, ALLR, and KZIA

How does Cardio Diagnostics compare to NeuroSense Therapeutics?

Summary

How does Cardio Diagnostics compare to SCYNEXIS?

Summary

How does Cardio Diagnostics compare to Aytu BioPharma?

Summary

How does Cardio Diagnostics compare to Allarity Therapeutics?

Summary

How does Cardio Diagnostics compare to Novogen?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cardio Diagnostics (CDIO) Competitors

CDIO vs. NRSN, SCYX, AYTU, ALLR, and KZIA

How does Cardio Diagnostics compare to NeuroSense Therapeutics?

Which has more volatility and risk, NRSN or CDIO?

Which has higher earnings and valuation, NRSN or CDIO?

Does the media refer more to NRSN or CDIO?

Do insiders and institutionals have more ownership in NRSN or CDIO?

Is NRSN or CDIO more profitable?

Do analysts rate NRSN or CDIO?

Summary

How does Cardio Diagnostics compare to SCYNEXIS?

Does the media refer more to SCYX or CDIO?

Which has higher earnings and valuation, SCYX or CDIO?

Do insiders and institutionals have more ownership in SCYX or CDIO?

Is SCYX or CDIO more profitable?

Which has more volatility and risk, SCYX or CDIO?

Do analysts rate SCYX or CDIO?

Summary

How does Cardio Diagnostics compare to Aytu BioPharma?

Is CDIO or AYTU more profitable?

Which has better earnings & valuation, CDIO or AYTU?

Do institutionals and insiders hold more shares of CDIO or AYTU?

Which has more risk and volatility, CDIO or AYTU?

Does the media prefer CDIO or AYTU?

Do analysts rate CDIO or AYTU?

Summary

How does Cardio Diagnostics compare to Allarity Therapeutics?

Is CDIO or ALLR more profitable?

Which has higher valuation & earnings, CDIO or ALLR?

Do insiders and institutionals believe in CDIO or ALLR?

Which has more risk & volatility, CDIO or ALLR?

Does the media prefer CDIO or ALLR?

Do analysts prefer CDIO or ALLR?

Summary

How does Cardio Diagnostics compare to Novogen?

Does the media favor KZIA or CDIO?

Do analysts prefer KZIA or CDIO?

Do insiders & institutionals hold more shares of KZIA or CDIO?

Which has more risk and volatility, KZIA or CDIO?

Is KZIA or CDIO more profitable?

Which has stronger earnings & valuation, KZIA or CDIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDIO vs. The Competition

Cardio Diagnostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools